The BalancedInvestor Club

RPRX Market Analysis

Overview

Fundamentals

P/E ratio28.93Forward 45.66
EPS (TTM)$1.9023.2% YoY
Profit margin33.9%HEALTHCARE
Market cap$31.65BLarge cap

Wall Street coverage

$59.25median target· current $27.00 (+119.4%)10 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
45.66
PEG ratio
2.06
P/B
3.55
P/S (TTM)
12.97
EV/EBITDA
18.85

Profitability & growth

ROE (TTM)
13.8%
Operating margin
100.3%
Revenue growth YoY
11.0%
Dividend yield
1.7%
Beta
0.40
Last earnings
May 6, 2026 · Estimate $0.67 · Reported $0.53
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Royalty Pharma Plc

Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.

Classification

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
110 EAST 59TH STREET, NEW YORK, NY
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$31.65B
Shares outstanding$443.3M
52W high$56.07
52W low$32.67

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer